Cargando…
Recalcitrant Ulcerative Pyoderma Gangrenosum of the Leg Responsive to Tildrakizumab: A Case Report
Elevated levels of inflammatory mediators—including the interleukin IL-23—are implicated in the pathogenesis of pyoderma gangrenosum (PG), an autoinflammatory neutrophilic dermatosis characterized by rapidly enlarging, suppurative ulcers and cribriform scarring. Here, we present the first case repor...
Autores principales: | Leow, Liang Joo, Zubrzycki, Nicolas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9419888/ https://www.ncbi.nlm.nih.gov/pubmed/36039180 http://dx.doi.org/10.2147/CCID.S374534 |
Ejemplares similares
-
Treatment of Recalcitrant Pyoderma Gangrenosum with Ulcerative Colitis by Adalimumab Injection
por: Lee, Jin-Hyup, et al.
Publicado: (2017) -
Ustekinumab for the treatment of recalcitrant pyoderma gangrenosum: A case report
por: Vallerand, Isabelle A, et al.
Publicado: (2019) -
Guselkumab as a treatment option for recalcitrant pyoderma gangrenosum
por: Baier, Cassandra, et al.
Publicado: (2020) -
Adalimumab Therapy for Recalcitrant Pyoderma Gangrenosum
por: Fonder, Margaret A., et al.
Publicado: (2006) -
Recalcitrant pyoderma gangrenosum treated with parenteral iron sucrose therapy
por: Buhalog, Brittany, et al.
Publicado: (2015)